Cryoport, Inc., a cryogenic logistics company dedicated to the life sciences industry, will provide its cold chain logistics services to support Nohla Therapeutics’ clinical studies evaluating its universal donor cell therapy, NLA101, in patients with hematologic malignancies and other diseases.

Cryoport will provide global logistics support for Nohla’s Phase II trials, observing international best practices for transporting cryogenically preserved commodities. Cryoport’s cryogenic logistics solutions include Cryoport Express shippers, SmartPak II Condition Monitoring System, Cryoportal Logistics Management Platform and 24/7/365 logistics support. These capabilities will allow Nohla to monitor its shipments and track the conditions and location of its biological commodities in transit, and to deploy intervention to mitigate any potential logistics risks.

Mr. Jerrell Shelton, chief executive officer of Cryoport, Inc., said, “Umbilical cord blood is known to be a useful source for blood stem cells and has been used to treat patients with certain blood diseases. Nohla Therapeutics is pioneering new universal donor off-the-shelf cord blood therapies designed to save lives, with a focus on individuals with hematologic malignancies, and we are proud that Nohla has selected Cryoport’s advanced temperature controlled logistics solutions to support delivery of NLA101 to clinical trial sites. We look forward to working with Nohla and providing global logistics solutions.”

NLA101 is a regenerative cell therapy consisting of cells derived from umbilical cord blood, available off the shelf without the need for HLA matching to the recipient. A Phase II study is currently evaluating NLA101 in patients receiving a cord blood transplant. Nohla is also initiating a second randomized Phase II study evaluating NLA101 in acute myeloid leukemia (AML) patients at risk for myelosuppression following high-dose chemotherapy.